文献速递产科母胎医学

17α-羟孕酮己酸酯用于复发性早产的药物基因组学:病例对照研究

Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth: a case-control study.
PubMed 文献 · BJOG · 2017-01-31

研究比较接受17α-羟孕酮己酸酯(17-P)预防复发性早产的女性中,妊娠延长成功与未成功者的母体基因型差异。99名有至少一次单胎自发性早产史的女性接受全外显子组测序,按两种定义分组分析。VAAST分析发现成功组与未成功组间多个基因变异有差异,基因本体通路分析显示早产相关基因和药物遗传学基因富集,但经Bonferroni校正后不显著。

要点

  • 按定义A(分娩孕周延迟≥3周)成功组70例、未成功组29例,1375个基因VAAST评分P<0.05。
  • 按定义B(达到足月)成功组47例、未成功组52例,1039个基因VAAST评分P<0.05。
  • 定义A的基因多归类为早产基因(P=0.026),定义B的基因多归类为药物遗传学基因(P=0.0018),Bonferroni校正后均不显著。

核心结论

  • 一种新的分析策略揭示了接受17-P后早期与晚期分娩女性之间的若干基因差异。

研究设计与样本

  • 病例对照研究,在美国三个三级保健中心进行,纳入99名有至少一次单胎自发性早产史并接受17-P的女性,全部进行全外显子组测序。

主要发现

  • 定义A(17-P治疗后分娩孕周较未治疗妊娠延迟≥3周为成功)成功组70例、未成功组29例,1375个基因VAAST评分P<0.05。
  • 定义B(17-P治疗后达到足月为成功)成功组47例、未成功组52例,1039个基因VAAST评分P<0.05。
  • PANTHER分析显示定义A的基因多归类为早产基因(P=0.026),定义B的基因多归类为药物遗传学基因(P=0.0018),Bonferroni校正后均不显著。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare maternal genotypes between women with and without significant prolongation of pregnancy in the setting of 17-alpha hydroxyprogesterone caproate (17-P) administration for the prevention of recurrent preterm birth (PTB). DESIGN: Case-control. SETTING: Three tertiary-care centres across the USA. POPULATION: Women (n = 99) with ≥ 1 prior singleton spontaneous PTB, receiving 17-P. METHODS: Women were classified as having successful prolongation of pregnancy during the 17-P treated pregnancy, in two ways: (1) Definition A: success/non-success based on difference in gestational age at delivery between 17-P-treated and untreated pregnancies (success: delivered ≥ 3 weeks later with 17-P) and (2) Definition B: success/non-success based on reaching term (success: delivered at term with 17-P). MAIN OUTCOME MEASURES: To assess genetic variation, all women underwent whole exome sequencing. Between-group sequence variation was analysed with the Variant Annotation, Analysis, and Search Tool (VAAST). Genes scored by VAAST with P < 0.05 were then analysed with two online tools: (1) Protein ANalysis THrough Evolutionary Relationships (PANTHER) and (2) Database for Annotation, Visualization, and Integrated Discovery (DAVID). RESULTS: Using Definition A, there were 70 women with successful prolongation and 29 without; 1375 genes scored by VAAST had P < 0.05. Using Definition B, 47 women had successful prolongation and 52 did not; 1039 genes scored by VAAST had P < 0.05. PANTHER revealed key differences in gene ontology pathways. Many genes from definition A were classified as prematurity genes (P = 0.026), and those from definition B as pharmacogenetic genes (P = 0.0018); (P, non-significant after Bonferroni correction). CONCLUSION: A novel analytic approach revealed several genetic differences among women delivering early vs later with 17-P. TWEETABLE ABSTRACT: Several key genetic differences are present in women with recurrent preterm birth despite 17-P treatment.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Manuck TA, Watkins WS, Esplin MS, et al. Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth: a case-control study. BJOG. 2017. PMID: 28139890. doi:10.1111/1471-0528.14485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。